BRÈVE

sur VALBIOTIS (EPA:ALVAL)

VALBIOTIS: Strong growth and promising prospects for 2026

Graphique de l'évolution du cours de l'action VALBIOTIS (EPA:ALVAL).

In 2025, VALBIOTIS SA recorded significant revenue growth in the fourth quarter thanks to targeted strategic execution. The results illustrate the progress of its business model in France and the development of two key partnerships in Asia and the Middle East. With expanded distribution and a notable increase in sales, particularly in e-commerce, the company highlights its growing presence in pharmacies and a 198% increase in average order value.

Internationally, VALBIOTIS has entered into strategic agreements, notably in Asia with Aika, to penetrate key markets, and in the Middle East with Mena Nutrition for exclusive distribution. In 2026, the company anticipates continued growth, built on solid foundations, to achieve its medium- and long-term financial ambitions. The company forecasts revenue exceeding €25 million in 2027 and aims to surpass €100 million by 2030.

R. H.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VALBIOTIS